From the Department of Cardiology Heart InstituteAsan Medical CenterUniversity of Ulan College of Medicine Seoul South Korea.
J Am Heart Assoc. 2021 Apr 6;10(7):e018548. doi: 10.1161/JAHA.120.018548. Epub 2021 Mar 19.
Background Postoperative atrial fibrillation (POAF) is common after cardiac surgery, but little is known about its incidence and natural course after noncardiac surgery. We evaluated the natural course and clinical impact of POAF and the long-term impact of anticoagulation therapy in patients without a history of atrial fibrillation (AF) undergoing noncardiac surgery. Methods and Results We retrospectively analyzed the database of Asan Medical Center (Seoul, Korea) to identify patients who developed new-onset POAF after undergoing noncardiac surgery between January 2006 and January 2016. The main outcomes were AF recurrence, thromboembolic event, and major bleeding during follow-up. Of 322 688 patients who underwent noncardiac surgery, 315 patients (mean age, 66.4 years; 64.4% male) had new-onset POAF with regular rhythm monitoring after discharge. AF recurred in 53 (16.8%) during 2 years of follow-up. Hypertension (hazard ratio, 2.12; =0.02), moderate-to-severe left atrial enlargement (hazard ratio, 2.33; =0.007) were independently associated with recurrence. Patients with recurrent AF had higher risks of thromboembolic events (11.2% versus 0.8%; <0.001) and major bleeding (26.9% versus 4.1%; <0.001) than those without recurrence. Patients with recurrent AF and without anticoagulation were especially predisposed to thromboembolic events (<0.001). Overall, anticoagulation therapy was not significantly associated with thromboembolic events (1.4% versus 2.5%, =0.95). Conclusions AF recurred in 16.8% of patients with POAF after noncardiac surgery. AF recurrence was associated with higher risks of adverse clinical outcomes. Considering the high risk of anticoagulation-related bleeding, the benefits of routine anticoagulation should be carefully weighed in this population. Active surveillance for AF recurrence is warranted.
心脏手术后常发生房性心动过速(POAF),但关于非心脏手术后其发生率和自然病程知之甚少。我们评估了无房颤(AF)病史的非心脏手术后患者 POAF 的自然病程和临床影响以及抗凝治疗的长期影响。
我们回顾性分析了 2006 年 1 月至 2016 年 1 月期间在韩国首尔 Asan 医疗中心接受非心脏手术后新发 POAF 的患者数据库。主要结局是随访期间 AF 复发、血栓栓塞事件和大出血。在接受非心脏手术的 322688 例患者中,315 例(平均年龄 66.4 岁;64.4%为男性)在出院后进行了常规节律监测,发现新发 POAF。在 2 年的随访中,53 例(16.8%)AF 复发。高血压(危险比,2.12;=0.02)、中重度左心房扩大(危险比,2.33;=0.007)与复发独立相关。AF 复发患者发生血栓栓塞事件(11.2%对 0.8%;<0.001)和大出血(26.9%对 4.1%;<0.001)的风险更高。无抗凝治疗的 AF 复发患者尤其易发生血栓栓塞事件(<0.001)。总体而言,抗凝治疗与血栓栓塞事件无显著相关性(1.4%对 2.5%;=0.95)。
非心脏手术后 POAF 患者中 16.8%的患者 AF 复发。AF 复发与不良临床结局风险增加相关。鉴于抗凝相关出血的高风险,在该人群中应谨慎权衡常规抗凝的获益。需要积极监测 AF 复发。